Keral (Dexketoprofen)

Dexketoprofen works by non‑selectively inhibiting the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which reduces the synthesis of prostaglandins. Lower prostaglandin levels diminish inflammation and interrupt pain signaling pathways, providing analgesic and anti‑inflammatory effects.

The dosage of Keral is determined by the prescribing clinician based on the patient’s condition, severity of pain, and clinical response. The prescriber will select the appropriate strength, route (intramuscular or intravenous), and frequency according to established medical guidelines.

Safety of dexketoprofen in pregnancy and lactation has not been fully established. It should only be used when the potential benefit justifies the possible risk to the fetus or infant, and only after consultation with a qualified healthcare professional.

To order Keral, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and required import documentation.

Dexketoprofen is the active enantiomer of ketoprofen, offering rapid analgesia with a potentially lower gastrointestinal side‑effect profile at equivalent doses. Compared with non‑selective NSAIDs such as ibuprofen, dexketoprofen may provide faster pain relief, but the overall safety considerations regarding renal, cardiovascular and bleeding risks remain similar.

Keral must be stored at 2‑8 °C in a refrigerator, protected from light. The product should not be frozen or shaken. Keep the vial in its original packaging until use to maintain sterility and potency.

Keral is administered by a qualified healthcare professional via intramuscular or intravenous injection. The route, volume, and rate of injection are selected according to the clinical situation and the prescribing information.

Serious risks include severe allergic reactions such as anaphylaxis, life‑threatening gastrointestinal bleeding or ulcer perforation, hepatic injury, acute renal failure, and cardiovascular events like myocardial infarction or stroke. Patients should be monitored for any signs of these conditions, especially if they have pre‑existing risk factors.

Keral should be avoided in individuals with known hypersensitivity to dexketoprofen or any NSAID, those with active gastrointestinal ulceration or bleeding, severe renal or hepatic impairment, and in patients for whom NSAIDs are contraindicated due to cardiovascular risk. Use in pregnancy and lactation is only permissible when clearly justified.